share_log

Alliance Global Partners Maintains Buy on Pluristem Therapeutics, Lowers Price Target to $4

Alliance Global Partners Maintains Buy on Pluristem Therapeutics, Lowers Price Target to $4

聯盟全球合作伙伴維持對Pluristem Therapeutics的買入,將目標股價下調至4美元
Benzinga Real-time News ·  2022/07/20 09:24

Alliance Global Partners analyst James Molloy maintains Pluristem Therapeutics (NASDAQ:PSTI) with a Buy and lowers the price target from $9.5 to $4.

Alliance Global Partners分析師詹姆斯·莫洛伊維持Pluristem Treateutics(納斯達克:PSTI)的買入,並將目標價從9.5美元下調至4美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論